CH622261A5 - - Google Patents

Download PDF

Info

Publication number
CH622261A5
CH622261A5 CH388676A CH388676A CH622261A5 CH 622261 A5 CH622261 A5 CH 622261A5 CH 388676 A CH388676 A CH 388676A CH 388676 A CH388676 A CH 388676A CH 622261 A5 CH622261 A5 CH 622261A5
Authority
CH
Switzerland
Prior art keywords
formula
compound
compounds
methyl
preparation
Prior art date
Application number
CH388676A
Other languages
German (de)
English (en)
Inventor
Willem Jacob Van Der Burg
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH622261(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of CH622261A5 publication Critical patent/CH622261A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CH388676A 1975-04-05 1976-03-29 CH622261A5 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (1)

Publication Number Publication Date
CH622261A5 true CH622261A5 (no) 1981-03-31

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
CH388676A CH622261A5 (no) 1975-04-05 1976-03-29

Country Status (17)

Country Link
US (1) US4062848A (no)
JP (1) JPS5942678B2 (no)
BE (1) BE840362A (no)
CA (1) CA1076571A (no)
CH (1) CH622261A5 (no)
DE (1) DE2614406A1 (no)
DK (1) DK142498B (no)
ES (2) ES446634A1 (no)
FI (1) FI62087C (no)
FR (1) FR2305986A1 (no)
GB (1) GB1543171A (no)
HU (1) HU179401B (no)
IE (1) IE42969B1 (no)
LU (1) LU74680A1 (no)
NL (2) NL189199C (no)
SE (1) SE422941B (no)
ZA (1) ZA761756B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
JPH055746Y2 (no) * 1988-04-27 1993-02-15
IE903557A1 (en) * 1989-10-05 1991-04-10 Sankyo Co Novel tetracyclic compounds having anti-allergic and¹anti-asthmatic activities, their preparation and use
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
PT1067934E (pt) * 1998-04-02 2004-03-31 Akzo Nobel Nv Solucao anti-depressiva liquida oral
IL146024A0 (en) 1999-04-19 2002-07-25 Teva Pharma Novel synthesis of piperazine ring
US6545149B2 (en) * 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
CN1356903A (zh) * 1999-04-19 2002-07-03 特瓦制药工业有限公司 含哌嗪环化合物的新型合成和结晶方法
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) * 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
WO2001042239A1 (fr) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Procede de preparation d'un compose pyridinemethanol
JP2003520237A (ja) * 2000-01-19 2003-07-02 アクゾ・ノベル・エヌ・ベー 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
AU780439B2 (en) 2000-02-11 2005-03-24 Merck Sharp & Dohme B.V. The use of mirtazapine for the treatment of sleep disorders
IN190478B (no) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ATE380884T1 (de) * 2001-02-12 2007-12-15 Organon Nv Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
US6774230B2 (en) 2001-03-01 2004-08-10 Teva Pharmaceutical Industries, Ltd. Methods for the preparation of mirtazapine intermediates
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
CA2565996A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
EP1776160A1 (en) * 2004-08-13 2007-04-25 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
CA2576299A1 (en) * 2004-08-24 2006-03-02 Sumitomo Chemical Company, Limited Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
NZ565683A (en) * 2005-07-08 2011-04-29 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MX2008006076A (es) 2005-11-09 2008-12-16 Combinatorx Inc Metodos, composiciones y kits para el tratamiento de condiciones medicas.
CA2627085A1 (en) * 2005-11-14 2007-05-18 Sumitomo Chemical Company, Limited Method for production 2-(4-methyl-2-phenylpiperazin-1-yl)pyridine-3-methanol
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
MX2008011434A (es) * 2006-03-06 2008-11-18 Organon Nv Metodo mejorado para retirar del tratamiento hormonal los sintomas vasomotores inducidos por eliminación de hormonas.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
BRPI0716604A2 (pt) * 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
WO2008125578A2 (en) 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of mirtazapine
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
EP2102203B1 (en) * 2007-04-11 2016-02-17 Merck Sharp & Dohme B.V. A method for the preparation of an enantiomerically pure benzazepine
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
EP2344498A1 (en) * 2008-10-22 2011-07-20 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (no) * 1966-03-12
NL7202963A (no) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
US4062848A (en) 1977-12-13
ZA761756B (en) 1977-03-30
SE422941B (sv) 1982-04-05
NL189199C (nl) 1993-02-01
NL940007I1 (nl) 1994-06-01
FR2305986B1 (no) 1980-06-13
ES446634A1 (es) 1977-11-01
HU179401B (en) 1982-10-28
DK142676A (no) 1976-10-06
LU74680A1 (no) 1976-11-11
NL940007I2 (nl) 1994-10-17
IE42969B1 (en) 1980-11-19
NL7504075A (nl) 1976-10-07
DE2614406A1 (de) 1976-10-14
DK142498C (no) 1981-07-06
JPS5942678B2 (ja) 1984-10-16
AU1236176A (en) 1977-09-29
GB1543171A (en) 1979-03-28
DE2614406C2 (no) 1992-02-20
DK142498B (da) 1980-11-10
FR2305986A1 (fr) 1976-10-29
ES459348A1 (es) 1978-03-16
BE840362A (fr) 1976-10-04
NL189199B (nl) 1992-09-01
SE7603931L (sv) 1976-10-06
JPS51122099A (en) 1976-10-25
CA1076571A (en) 1980-04-29
FI62087B (fi) 1982-07-30
IE42969L (en) 1976-10-05
FI62087C (fi) 1982-11-10
FI760884A (no) 1976-10-06

Similar Documents

Publication Publication Date Title
CH622261A5 (no)
DE69723846T2 (de) Verfahren zur Herstellung von Sildenafil
CH637382A5 (de) Verfahren zur herstellung neuer tetracyclischer pyridin- oder pyrrolderivate.
DE2111071A1 (de) Verfahren zur Herstellung neuer heterocyclischer Verbindungen
DE1795769B2 (de) 6,7A9-Tetrahydro-2H-pyrido [1,2-a] pyrimidinderivate, deren Salze mit Säuren und quaternär? Methosalze, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel
DE1670849B2 (de) Verfahren zur herstellung von 8-acylamino-1,2,3,4-tetrahydroisochinolinen
DE2505239C2 (no)
DE68903680T2 (de) 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion-2,4-derivate, deren herstellung und verwendung als heilmittel.
DE1695929C3 (de) 1 ^-Dihydro-1 -hydroxy^-imino^-amino-6-methylpyrimidine sowie ein Verfahren zu deren Herstellung
DE2141616A1 (de) Verfahren zur Herstellung von Chinazo lindenvaten und neue Chinazolindenvate
DE1967178C2 (de) Verfahren zur Herstellung von Chinuclidinyl-4-chinolinmethanolderivaten
DE2230154A1 (de) N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
DE1935671C3 (de) 2-Aminomethylindole und ihre Salze
DE1076691B (de) Verfahren zur Herstellung von Phenthiazinderivaten
CH630902A5 (en) Process for preparing novel derivatives of 1,2,3,4,4a,10b-hexahydrobenzo(f)isoquinoline.
DE2511599A1 (de) Pyrroldiazepine und verfahren zu ihrer herstellung
DE3120909C2 (de) Verfahren zur Herstellung von 7-(N-Äthyl-N-β-hydroxyäthylaminoäthyl)-8-benzyltheophyllin (Bamifyllin)
AT250338B (de) Verfahren zur Herstellung neuer, basischer Derivate von substituierten Benzofuran-2-carbonsäuren und deren Salzen
DE1795053A1 (de) Verfahren zur Herstellung von Verbindungen der Benzodiazepinreihe
DE1817794C3 (de) Verfahren zur Herstellung von 2-Benzyloxycarbonylglycylamidobenzophenonen
AT330373B (de) Verfahren zur herstellung von neuen 2- (heteroaryl-methyl) -5,9beta-dialkyl -6,7- benzomorphanen
AT378960B (de) Verfahren zur herstelllung von neuen imidazo (1,5-a) (1,4)diazepinverbindungen, ihren salzen und optisch aktiven formen
CH561211A5 (en) Antihypertensive 3-hydrazino pyrido(4,3-c)pyridazines - prepd. by reacting corresp 3-halo cpd. with hydrazines
DE1038047B (de) Verfahren zur Herstellung von N-aminoalkylierten Iminodibenzylen und deren Salzen
AT251765B (de) Verfahren zur Herstellung von neuen Yohimbanderivaten und von deren Salzen

Legal Events

Date Code Title Description
PL Patent ceased